论文部分内容阅读
目的:通过观察患者口服或皮下注射降糖药物后低血糖的发生情况,旨在探讨治疗老年糖尿病患者最有效、最安全及依从性最好的治疗方案。方法:将80例老年糖尿病患者随机分为口服降糖药物组和使用诺和锐30R组,每组各40例,观察并比较6个月后两组患者发生低血糖及其他不良反应的情况。结果:在口服药物组的40例患者中,发生低血糖的有28例,诱发乳酸酸中毒的有2例,继发性失效的有8例,继发肝损害的有2例;在使用诺和锐30R组的患者中,发生低血糖的有12例,继发肝损害的有1例,无乳酸酸中毒及继发性失效的情况发生,差异具有统计学意义。结论:对于老年糖尿病患者来说,使用诺和锐30R比口服降糖药物的效果好,低血糖发生率低,安全性高。
Objective: To observe the incidence of hypoglycemia after oral or hypodermic injection of hypoglycemic agents in patients with diabetes mellitus, in order to explore the most effective, safest and most compliant treatment for the treatment of elderly patients with diabetes mellitus. Methods: Eighty elderly patients with diabetes mellitus were randomly divided into oral hypoglycemic group and Noro Rui 30R group, 40 cases in each group. The incidence of hypoglycemia and other adverse reactions in both groups were observed and compared after 6 months. RESULTS: Of the 40 patients in the oral medication group, 28 had hypoglycemia, 2 had lactic acidosis, 8 had secondary failure, and 2 had secondary liver damage. In Rui 30R group, there were 12 cases of hypoglycemia, 1 case of secondary liver damage, no lactic acidosis and secondary failure, the difference was statistically significant. CONCLUSIONS: For older patients with diabetes, the use of Novo-Ruo 30R has good oral hypoglycemic agents, low incidence of hypoglycemia and high safety.